ARTIS DEAN RICHARD 4

What Happened Artis Dean Richard, Annexon’s Executive Vice President & Chief Scientific Officer, received two equity awards on February 19, 2026: 62,500 restricted stock units (RSUs) and a 250,000-share derivative award (option grant). Both entries are reported at $0.00 per share, indicating they were granted as compensation rather than purchased. No exercise or sale occurred — these are awards/vesting arrangements, not open-market buys or sales.

Key Details

• Transaction date: 2026-02-19; Filing date: 2026-02-23 (filed within the standard 2-business-day window).
• Reported price: $0.00 for both the 62,500 RSUs and the 250,000-share derivative award (total reported cash outlay = $0).
• Shares owned after transaction: not specified in the filing.
• Footnote F1 (RSUs): 1 RSU = 1 share on vesting; 1/3 of the RSUs vest annually on Feb 19, starting Feb 19, 2027, subject to continued service.
• Footnote F2 (derivative/option): vests 1/48th monthly beginning Feb 19, 2026, fully vesting after 4 years, subject to continued service.
• Transaction type codes reported as A (award/grant); no indication of immediate sale, exercise, or tax-withholding in this Form 4.

Context RSU and option grants are common components of executive compensation and do not represent open-market buying or selling. The RSU award vests in annual tranches (1/3 per year), while the option-like award vests monthly over four years — meaning the insider must remain employed for vesting. Because these were grants (not purchases), they are not necessarily a direct signal of the insider’s view of short-term stock direction; they primarily reflect compensation and retention incentives.